Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia. It involves the gradual destruction of brain cells, leading to declines in memory, thinking, language, and behavior. The disease is marked by the accumulation of amyloid plaques and tau tangles in the brain, which disrupt communication between neurons and eventually cause cell death.
AD typically begins with mild memory loss and advances to severe cognitive and functional impairment. It is not a normal part of aging, though age is the strongest known risk factor. The disease can begin years before symptoms appear, with brain changes occurring silently.
Other Name(s)
Alzheimer’s Dementia
Senile Dementia of the Alzheimer Type (SDAT)
Early-Onset Alzheimer’s (if before age 65)
Late-Onset Alzheimer’s (after age 65)
Difference Between Alzheimer’s and Similar Conditions
NIH Alzheimer’s Studies
| Condition |
Key Difference from Alzheimer’s Disease |
| Dementia |
Umbrella term; Alzheimer’s is one type of dementia |
| Vascular Dementia |
Caused by stroke or reduced blood flow |
| Lewy Body Dementia |
Prominent hallucinations and movement issues |
| Frontotemporal Dementia |
Early personality/language changes |
| Depression |
May mimic memory loss but lacks progressive decline |
Normal vs. Abnormal State
Normal Aging: Occasional forgetfulness, slower processing
Alzheimer’s: Persistent memory loss, confusion, impaired judgment, personality changes
Types of Alzheimer’s Disease
| Type |
Description |
| Early-Onset |
Symptoms before age 65; often genetic |
| Late-Onset |
Most common; after age 65 |
| Familial Alzheimer’s |
Rare inherited form; strong genetic link |
| Sporadic Alzheimer’s |
No clear family history; most cases fall here |
Causes
Amyloid plaque buildup
Tau protein tangles
Genetic mutations (e.g., APOE-e4 gene)
Inflammation and oxidative stress
Vascular damage
Lifestyle and environmental factors
Risk Factors
NIH Alzheimer’s Studies
Age (especially >65)
Family history/genetics
Head trauma
Cardiovascular disease
Diabetes
Smoking
Sedentary lifestyle
Poor sleep
Low education level
Who Is Vulnerable/Susceptible?
Older adults (especially 75+)
People with Down syndrome
Individuals with APOE-e4 gene
Women (higher prevalence)
Ethnic minorities (diagnosis disparities)
Complications
Inability to perform daily tasks
Wandering and getting lost
Depression and anxiety
Aggression and paranoia
Malnutrition and dehydration
Infections (e.g., pneumonia)
Falls and injuries
Prevention
No guaranteed prevention
Risk reduction through:
Regular exercise
Heart-healthy diet (e.g., Mediterranean)
Cognitive stimulation
Social engagement
Blood pressure and cholesterol control
Avoiding smoking and excessive alcohol
How Condition Develops
Silent brain changes (plaques/tangles)
Mild cognitive impairment (MCI)
Early-stage Alzheimer’s (memory loss)
Moderate-stage (confusion, behavior changes)
Late-stage (complete dependence, loss of bodily functions)
Common Symptoms
Memory loss (especially recent events)
Difficulty with problem-solving
Trouble with language and communication
Disorientation (time/place)
Mood and personality changes
Poor judgment
Withdrawal from social activities
Repetitive behaviors
Other Conditions That Can Mimic Alzheimer’s
Depression
Vitamin B12 deficiency
Thyroid disorders
Medication side effects
Stroke
Parkinson’s disease
Normal pressure hydrocephalus
Diagnosis and Tests
UNM Center for Memory & Aging
UNM Center for Memory & Aging
Clinical history and cognitive assessments
Mini-Mental State Exam (MMSE)
Montreal Cognitive Assessment (MoCA)
Brain imaging (MRI, CT, PET scans)
Blood tests (rule out other causes)
Genetic testing (if early-onset suspected)
Biomarker testing (amyloid/tau in CSF or blood)
Treatment and Therapies
No cure, but treatments may slow progression or manage symptoms
FDA-approved medications:
Cholinesterase inhibitors (donepezil, rivastigmine)
NMDA receptor antagonist (memantine)
Anti-amyloid therapies (e.g., lecanemab, aducanumab)
Supportive therapies:
Cognitive stimulation
Behavioral therapy
Occupational therapy
Caregiver support
Statistics & Disparity
~6.9 million Americans aged 65+ affected
1 in 3 seniors dies with Alzheimer’s or another dementia
Higher prevalence in women and African Americans
Underdiagnosis in Hispanic and rural populations
Economic burden: $345 billion annually in U.S.
Alternative/Complementary Treatment
Music and art therapy
Aromatherapy
Mindfulness and meditation
Nutritional supplements (e.g., omega-3s, vitamin E)
Acupuncture (limited evidence)
New Medications for Treatment
Lecanemab (Leqembi): Anti-amyloid therapy approved for early-stage AD
Donanemab: Under FDA review
Aducanumab (Aduhelm): Controversial approval; limited use
Anti-tau therapies: In clinical trials
Cost of Treatment and/or Management
| Item |
Estimated Cost (USD) |
| Medications |
$200–$1,000/month |
| Imaging and diagnostics |
$1,000–$5,000 |
| Home care services |
$20–$30/hour |
| Long-term care facility |
$4,000–$10,000/month |
Insurance Coverage
Most plans cover:
Diagnostic testing
FDA-approved medications
Cognitive therapy
Hospice and palliative care
Caregiver support (limited)
Prognosis
Progressive and irreversible
Average survival: 4–8 years after diagnosis
Some live up to 20 years
Early diagnosis improves planning and quality of life
What Happens if No Treatment?
Faster cognitive decline
Increased behavioral issues
Higher caregiver burden
Early institutionalization
Increased mortality risk
Related Images
CDC Alzheimer’s Overview
Mayo Clinic Alzheimer’s Symptoms
MedlinePlus Alzheimer’s Gallery
Survival Rate / Mortality Rate
| Stage |
5-Year Survival Rate |
| Mild |
~75% |
| Moderate |
~50% |
| Severe |
~20–30% |
Palliative Care
Focus on comfort and dignity
Pain and symptom management
Emotional and spiritual support
Advance care planning
Hospice services (late-stage)
Living with Alzheimer’s
Structured routines
Safety modifications at home
Memory aids and reminders
Support groups
Legal and financial planning
Caregiver education
New Treatment Approaches
Anti-tau therapies
Gene editing (CRISPR research)
Stem cell therapy
AI-assisted diagnostics
Digital therapeutics (cognitive apps)
Related Issues
Depression and anxiety
Caregiver burnout
Elder abuse risk
Financial exploitation
Wandering and safety concerns
Ongoing Research
Biomarker discovery
Lifestyle interventions
Neuroinflammation studies
Brain imaging advancements
Early detection tools
Clinical Trials & Participation
ClinicalTrials.gov: Alzheimer’s
NIH Alzheimer’s Research
Alzheimer’s Association Trials
Source: America Healthline Medical Team
